Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
Read original at benzingaStocks · News reference
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Read original at benzinga12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings came out
Read original at benzingaMedicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.
Read original at benzingaMedicus Pharma Announces Co-Development And License Agreement With Pfizer For CD228-Targeting ADC PF-08046031, Paying $12M Upfront And $15M In One Year; Pfizer Eligible For Over $1B In Milestones Plus Royalties
https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm
Read original at benzingaMedicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of $(0.43) per share from
Read original at benzinga